For a patient with gastro‑oesophageal reflux disease refractory to lifestyle changes and over‑the‑counter antacids, which medication is appropriate: famotidine (Pepcid), metoclopramide (Reglan), esomeprazole (Protonix), or sucralfate (Carafate)?

Prescribe Protonix (or another PPI)

For a patient with GERD unrelieved by lifestyle changes and OTC antacids, you should prescribe a proton pump inhibitor (PPI) such as Protonix (pantoprazole), as PPIs are Grade A recommended and significantly more effective than H2-receptor antagonists (like Pepcid), which are in turn more effective than placebo. 1 Reglan (metoclopramide) receives a Grade D recommendation (recommend against) for GERD treatment, and Carafate (sucralfate) has failed to demonstrate efficacy in controlled trials. 1, 2

Why PPIs Are First-Line

The American Gastroenterological Association guidelines provide Grade A evidence (the highest level) that PPIs are superior to H2-receptor antagonists for both healing esophagitis and achieving symptomatic relief in GERD. 1 This hierarchy is clear: PPIs > H2RAs > placebo for antisecretory therapy in GERD syndromes.

More recent guidelines from the American College of Physicians (2012) reinforce this approach, stating that empirical acid-suppressive therapy with once-daily PPIs is warranted for patients with typical GERD symptoms like heartburn or regurgitation. 3 Any PPI can be used (esomeprazole, lansoprazole, omeprazole, pantoprazole/Protonix, or rabeprazole) because absolute differences in efficacy are small. 3

Dosing Strategy

• Start with once-daily PPI taken 30-60 minutes before a meal for 4-8 weeks 3, 4
• If inadequate response: Escalate to twice-daily PPI dosing (though not FDA-approved, this is unanimously recommended by expert opinion based on pharmacodynamics) 1
• Maximum empirical therapy: Twice-daily PPI for 4-8 weeks; if symptoms persist, consider this a treatment failure requiring endoscopy 1, 3

Why NOT the Other Options

Pepcid (Famotidine - H2RA)

While H2-receptor antagonists like famotidine are more effective than placebo, they are significantly less effective than PPIs for both symptom control and healing esophagitis. 1 The guidelines clearly establish the superiority of PPIs as Grade A evidence. Additionally, H2RAs can develop tachyphylaxis (tolerance) within 6 weeks of continuous use, limiting their long-term effectiveness. 5

Reglan (Metoclopramide)

Metoclopramide receives a Grade D recommendation—meaning it is recommended AGAINST as monotherapy or adjunctive therapy for GERD. 1 A 1996 study showed that adding metoclopramide to ranitidine significantly increased adverse events without improving outcomes compared to omeprazole alone. 6 The FDA label for Reglan indicates therapy should not exceed 12 weeks and lists significant side effects including drowsiness, restlessness, and extrapyramidal reactions. 7 Prokinetics have not demonstrated benefits that outweigh their risks in GERD treatment. 5

Carafate (Sucralfate)

Sucralfate, a mucosal protective agent, failed to heal refractory esophagitis in a controlled trial comparing it to high-dose famotidine. Complete healing occurred in 0 of 8 patients on sucralfate versus 5 of 8 on famotidine (p<0.05). 2 The study concluded that antisecretory therapy is more effective than mucosal protection for refractory peptic esophagitis. There is no robust evidence supporting sucralfate as effective treatment for GERD.

Clinical Pearls

• Timing matters: PPIs should be taken 30-60 minutes before meals for optimal efficacy 3
• Response assessment: Evaluate symptom control at 4-8 weeks 3, 4
• Dose titration: If symptoms resolve, attempt to wean to the lowest effective dose or on-demand therapy 4
• When to escalate: If once-daily PPI fails, increase to twice-daily before switching agents 1, 3
• Red flags requiring endoscopy: Dysphagia, bleeding, anemia, weight loss, recurrent vomiting, or failure of twice-daily PPI therapy 3

Common Pitfalls to Avoid

1. Don't start with H2RAs when PPIs are indicated: The evidence hierarchy is clear—PPIs are first-line for GERD unresponsive to lifestyle modifications and antacids
2. Don't use metoclopramide for GERD: It has a Grade D recommendation with significant adverse effects
3. Don't forget proper PPI timing: Taking PPIs with meals reduces efficacy
4. Don't continue empirical therapy beyond twice-daily PPI: This represents treatment failure and warrants objective testing 1, 3